Table 3.

Patient characteristics by treatment group in the validation cohort

Characteristics	IFX (n=112)	RTX (n=94)	P value
Age (years), median (IQR)	52 (43–58)	62 (52–67)	<0.001
Sex (male), n (%)	52 (46.4)	27 (28.7)	0.010
Concomitant csDMARD, n (%)	58 (51)	42 (46.7)	0.330
Concomitant corticosteroid, n (%)	3 (2.7)	16 (12)	0.001
Diagnoses, n (%)			<0.001
Rheumatoid arthritis	25 (22.3)	94 (100.0)
Axial spondyloarthritis	67 (59.8)	0 (0.0)
Psoriatic arthritis	20 (17.9)	0 (0.0)

Baseline patient characteristics were compared using Wilcoxon test for continuous variables and Fisher’s exact test for categorical variables.

csDMARD, conventional synthetic disease-modifying antirheumatoid drug; IFX, infliximab; RTX, rituximab.